&#39Disturbing&#39

'Disturbing' Disparity in Use of Key Breast Cancer Drug
The purpose of the study was to investigate the rates and patterns of receipt of trastuzumab in patients with early HER2-positive breast cancer (stages I-III) diagnosed in 2010 and 2011. Using the SEER-Medicare database, investigators examined a ... [...]
1
Like
Save